China's Stemirna Halts mRNA Cancer Vaccine Trial

China's Stemirna Therapeutics has paused an early-stage trial for a novel cancer vaccine, signaling a setback for the company amid financial challenges, Andrew Silver reported for Reuters.

The study for Stemirna's personalized cancer vaccine SW1115C has been reportedly on hold for several months.

Vinod Ganju, an oncologist at Paso Medical in Australia and one of the principal trial investigators for Stemirna's personalized cancer vaccine SW1115C3, revealed that the study had been on hold for several months.

There has been no communication from Stemirna regarding the trial status, according to Ganju.

Mihitha Ariyapperuma, an oncologist at One Clinical Research and another principal investigator, stated that the trial never gained momentum in the country.

Stemirna has faced financial difficulties, with reports emerging in December of delayed wage payments. Additionally, its COVID vaccine is yet to receive approval from Chinese regulators.

WEEKLY FEATURE : Jose Mari Chan And The Christmas Anthem